Table 5.

Cardiology‐Specific Future Research Directions

Why do cardiac rhabdomyomas regress and other hamartomas do not?

Do cardiac rhabdomyomas completely resolve?

What is the incidence of sudden death? Malignant arrhythmia?

Do TSC1 and TSC2 genotypes predict cardiac phenotype or outcome?

Does treatment with mTOR inhibitors decrease the long‐term risk of arrhythmia?

What is the incidence of latent left ventricular hypertrophy and/or dysfunction?

What is the incidence and natural history of lipidemia in TSC?

mTOR indicates mammalian target of rapamycin; TSC, tuberous sclerosis complex.